Xeljanz xr and Skin hypertrophy - a phase IV clinical study of FDA data

Summary:

Skin hypertrophy is found among people who take Xeljanz xr, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Xeljanz xr and have Skin hypertrophy. It is created by eHealthMe based on reports of 62,790 people who have side effects when taking Xeljanz xr from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Aug, 01, 2022

62,790 people reported to have side effects when taking Xeljanz xr.
Among them, 9 people (0.01%) have Skin hypertrophy.


What is Xeljanz xr?

Xeljanz xr has active ingredients of tofacitinib citrate. eHealthMe is studying from 62,822 Xeljanz xr users for its effectiveness, alternative drugs and more.

What is Skin hypertrophy?

Skin hypertrophy (skin cells enlarges) is found to be associated with 980 drugs and 496 conditions by eHealthMe.

Number of Xeljanz xr and Skin hypertrophy reports submitted per year:

Could Xeljanz xr cause Skin hypertrophy?

Gender of people who have Skin hypertrophy when taking Xeljanz xr *:

  • female: 88.89 %
  • male: 11.11 %

Age of people who have Skin hypertrophy when taking Xeljanz xr *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Xeljanz xr *:

  1. Enbrel: 1 person, 11.11%
  2. Augmentin: 1 person, 11.11%

Common side effects people have besides Skin hypertrophy *:

  1. Joint Pain: 5 people, 55.56%
  2. Joint Swelling: 3 people, 33.33%
  3. Mycobacterium Avium Complex Infection: 2 people, 22.22%
  4. Tenderness (pain or discomfort when an affected area is touched): 2 people, 22.22%
  5. Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 2 people, 22.22%
  6. Diarrhea: 2 people, 22.22%
  7. Rashes (redness): 2 people, 22.22%
  8. Fainting (loss of consciousness and postural tone): 2 people, 22.22%
  9. High Blood Pressure: 1 person, 11.11%
  10. Head Injury: 1 person, 11.11%

Common conditions people have *:

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 33.33%
  2. Upper Respiratory Tract Infection: 1 person, 11.11%
  3. Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 11.11%
  4. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Xeljanz xr and have Skin hypertrophy?

Check whether Skin hypertrophy is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Xeljanz xr:

Skin hypertrophy treatments and more:

COVID vaccines that are related to Skin hypertrophy:

How severe was Skin hypertrophy and when was it recovered:

Expand to all the drugs that have ingredients of tofacitinib citrate:

Common drugs associated with Skin hypertrophy:

All the drugs that are associated with Skin hypertrophy:

Common conditions associated with Skin hypertrophy:

All the conditions that are associated with Skin hypertrophy:

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz xr) and Xeljanz xr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: